Grifols, S.A.

GRFS Healthcare Drug Manufacturers General

Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024. In the quarter to June 2026, revenue grew 5.76%, EPS grew 466.9%, free cash flow grew 300.5% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

7.64 0.10 +1.33%
Market cap
$2.0B
P/E
8.5×
Fwd P/E
—
Dividend yield
1.24%
F-score
5/9
Altman Z
1.38
Beneish M
−2.59
Dividend safety
54/100

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Total current assets
6,168.12 6,149.28 5,740.72 6,252.18
Total non-current assets
17,190.52 17,350.01 16,561.43 16,954.89
Total Assets
23,358.64 23,499.29 22,302.16 23,207.07
Total current liabilities
2,599.80 2,485.93 2,284.30 2,518.80
Total non-current liabilities
11,480.50 11,829.23 11,415.83 11,865.45
Total liabilities
14,080.30 14,315.16 13,700.12 14,384.26
Common Equity (Total)
9,278.35 9,184.13 8,602.03 8,822.81
Shareholders Equity (Total)
9,278.35 9,184.13 8,602.03 8,822.81
Total Debt
10,878.22 11,316.60 10,910.09 11,324.21

Show all line items

In millions of $ except per-share values · columns are period end dates